Wednesday, October 31, 2012

Mobile Video Conferencing

Video Conferencing An Inflection Point

*Apple Facetime 3G only for iOS 6 on iPhone 4S, iPhone 5, new iPad 3, iPad 4, iPad mini, best video quality with hardware DSP acceleration
Google+ Hangouts using Vidyo H.264 SVC
ooVoo comparison
fring Dynamic Video Quality
FriendCaller
*skype SD VP8, HD H264, audio from G.729 to SVOPC to SILK
*Tango
WeChat 微信
Camfrog 
VPHO
VSir 千里眼视频通信
eSky.co

Vidyo Mobile with other vidyo devices, 480x270 encoding, 720p decoding, H264 Scalable Video Coding, Speex wideband audio codec 32kbps

Google Voice no iPad, video chat only on PC, H264
qik video only on certain mobile phones

Video Conferencing on PC

Viber using Spirit DSP no video

Full-HD Voice: Understanding the AAC codecs behind a new era in communication AAC Enhanced Low Delay v2
AAC-ELD > Opus (CELT+SILK) > CELT (ogg, low latency) > G.719 (Polycom) > AAC-LD > SILK (Skype, speech) > G722.2 (AMR-WB) > Speex

Audio/Video Files, Codecs and Containers

Tuesday, October 16, 2012

Medical facilities, departments, healthcare professionals, and specialties

ABMS specialty American Board of Medical Specialties, ABMS Guide to Medical Specialties

ABMS Board Certification Report

General Certificate(s)Subspecialty Certificates
American Board of Allergy and Immunology
Allergy and ImmunologyNo Subspecialties
American Board of Anesthesiology
AnesthesiologyCritical Care Medicine
Hospice and Palliative Medicine
Pain Medicine
Pediatric Anesthesiology
Sleep Medicine
American Board of Colon and Rectal Surgery
Colon and Rectal SurgeryNo Subspecialties
American Board of Dermatology
DermatologyDermatopathology
Pediatric Dermatology
American Board of Emergency Medicine
Emergency MedicineAnesthesiology Critical Care Medicine1
Emergency Medical Services
Hospice and Palliative Medicine
Internal Medicine-Critical Care Medicine
Medical Toxicology
Pain Medicine
Pediatric Emergency Medicine
Sports Medicine
Undersea and Hyperbaric Medicine
American Board of Family Medicine
Family MedicineAdolescent Medicine
Geriatric Medicine
Hospice and Palliative Medicine
Pain Medicine
Sleep Medicine
Sports Medicine
American Board of Internal Medicine
Internal MedicineAdolescent Medicine
Adult Congenital Heart Disease2
Advanced Heart Failure and Transplant
    Cardiology
Cardiovascular Disease
Clinical Cardiac Electrophysiology
Critical Care Medicine
Endocrinology, Diabetes and Metabolism
Gastroenterology
Geriatric Medicine
Hematology
Hospice and Palliative Medicine
Infectious Disease
Interventional Cardiology
Medical Oncology
Nephrology
Pulmonary Disease
Rheumatology
Sleep Medicine
Sports Medicine
Transplant Hepatology
American Board of Medical Genetics
Clinical Biochemical Genetics*
Clinical Cytogenetics*
Clinical Genetics (MD)*
Clinical Molecular Genetics*
Medical Biochemical Genetics
Molecular Genetic Pathology
American Board of Neurological Surgery
Neurological SurgeryNo Subspecialties
American Board of Nuclear Medicine
Nuclear MedicineNo Subspecialties
American Board of Obstetrics and Gynecology
Obstetrics and GynecologyCritical Care Medicine
Female Pelvic Medicine and
     Reconstructive Surgery
Gynecologic Oncology
Hospice and Palliative Medicine
Maternal and Fetal Medicine
Reproductive Endocrinology/Infertility
American Board of Ophthalmology
OphthalmologyNo Subspecialties
American Board of Orthopaedic Surgery
Orthopaedic SurgeryOrthopaedic Sports Medicine
Surgery of the Hand
American Board of Otolaryngology
OtolaryngologyNeurotology
Pediatric Otolaryngology
Plastic Surgery Within the Head and Neck
Sleep Medicine
American Board of Pathology
Pathology-Anatomic/Pathology-Clinical*
Pathology - Anatomic*
Pathology - Clinical*
Blood Banking/Transfusion Medicine
Clinical Informatics
Cytopathology
Dermatopathology
Neuropathology
Pathology - Chemical
Pathology - Forensic
Pathology - Hematology
Pathology - Medical Microbiology
Pathology - Molecular Genetic
Pathology - Pediatric
American Board of Pediatrics
PediatricsAdolescent Medicine
Child Abuse Pediatrics
Developmental-Behavioral Pediatrics
Hospice and Palliative Medicine
Medical Toxicology
Neonatal-Perinatal Medicine
Pediatric Cardiology
Pediatric Critical Care Medicine
Pediatric Emergency Medicine
Pediatric Endocrinology
Pediatric Gastroenterology
Pediatric Hematology-Oncology
Pediatric Infectious Diseases
Pediatric Nephrology
Pediatric Pulmonology
Pediatric Rheumatology
Pediatric Transplant Hepatology
Sleep Medicine
Sports Medicine
American Board of Physical Medicine and Rehabilitation
Physical Medicine and RehabilitationBrain Injury Medicine3
Hospice and Palliative Medicine
Neuromuscular Medicine
Pain Medicine
Pediatric Rehabilitation Medicine
Spinal Cord Injury Medicine
Sports Medicine
American Board of Plastic Surgery
Plastic SurgeryPlastic Surgery Within the Head and Neck
Surgery of the Hand
American Board of Preventive Medicine
Aerospace Medicine*
Occupational Medicine*
Public Health and General Preventive Medicine*
Clinical Informatics
Medical Toxicology
Undersea and Hyperbaric Medicine
American Board of Psychiatry and Neurology
Psychiatry*
Neurology*
Neurology with Special Qualification
     in Child Neurology*
Addiction Psychiatry
Brain Injury Medicine3
Child and Adolescent Psychiatry
Clinical Neurophysiology
Epilepsy
Forensic Psychiatry
Geriatric Psychiatry
Hospice and Palliative Medicine
Neurodevelopmental Disabilities
Neuromuscular Medicine
Pain Medicine
Psychosomatic Medicine
Sleep Medicine
Vascular Neurology
American Board of Radiology
Diagnostic Radiology*
Interventional Radiology and Diagnostic Radiology*3
Radiation Oncology*
Medical Physics*
Hospice and Palliative Medicine
Neuroradiology
Nuclear Radiology
Pain Medicine
Pediatric Radiology
Vascular and Interventional Radiology
American Board of Surgery
Surgery*
Vascular Surgery*
Complex General Surgical Oncology4
Hospice and Palliative Medicine
Pediatric Surgery
Surgery of the Hand
Surgical Critical Care
American Board of Thoracic Surgery
Thoracic and Cardiac SurgeryCongenital Cardiac Surgery
American Board of Urology
UrologyFemale Pelvic Medicine and
     Reconstructive Surgery
Pediatric Urology

*Specific disciplines within the specialty where certification is offered.
1Approved 2013; first issue 2014
2Approved 2012; first issue to be determined
3Approved 2011; first issue 2014
4Approved 2011; first issue to be determined
 
Residency (PGY), Attending physician 

見習 Clerk 實習 Intern 住院 Resident 總住院 CR 研究醫師 Fellow 主治 VS 主任 Chief  

National Resident Matching Program: Main Residency Match Data & Reports
PGY, Residence, Fellowship, 2015 Advance Data Tables: Main Residency Match


Residency Length
Transitional/Preliminary: 1 year
Emergency Medicine: 3-4 years
Family Practice: 3 years
Internal Medicine: 3 years
Pediatrics: 3 years
Obstetrics-Gynecology: 4 years
Pathology: 4 years
Psychiatry: 4 years
Anesthesiology: 3 years plus PGY-1 Transitional/Preliminary
Dermatology: 3 years plus PGY-1 Transitional/Preliminary
Neurology: 3 years plus PGY-1 Transitional/Preliminary
Opthamology: 3 years plus PGY-1 Transitional/Preliminary
Physical Medicine: 3 years plus PGY-1 Transitional/Preliminary
Diagnostic Radiology: 4 years plus PGY-1 Transitional/Preliminary
Radiation Oncology: 4 years plus PGY-1 Transitional/Preliminary
General Surgery: 5 years
Orthopaeic Surgery:  5 years (includes 1 year of general surgery)
Otolaryngology: 5 years (includes 1 year of general surgery)
Plastic Surgery: 5-6 years (includes 1 year of general surgery)
Neurological Surgery: 6 years (includes 1 year of general surgery)


台灣 行政院 衛生福利部>前往本部各單位>醫事司>醫院評鑑資訊公開  Taiwan Hospital Review

健保局 > 一般民眾 > 健保醫療服務 > 健保特約醫事機構查詢 醫學中心, 區域醫院, 地區醫院, 診所 Taiwan Health Insurance Medical Centers, Hospitals, Clinics

財團法人醫院評鑑暨醫療品質策進會: 行政院衛生署97-100年度新制醫院評鑑及新制教學醫院評鑑合格名單

醫療資源暨地理資訊查詢 Taiwan Medical Resource GIS

台北市立萬芳醫院-委託財團法人私立臺北醫學大學辦理 Taipei WanFang Hospital

家庭醫學科 Family Medicine 內科 Internal Medicine
外科 Surgery 小兒科 Pediatrics
婦產科 Obstetrics and Gynecology 骨科 Orthopaedic Surgery
神經科 Neurology 神經外科 Neurological Surgery
泌尿科 Urology 耳鼻喉科 Otolaryngology
眼科 Ophthalmology 皮膚科 Dermatology
精神科 Psychiatry 復健科 Physical Medicine and Rehabilitation
麻醉科 Anesthesiology 放射線科(診斷) Diagnostic Radiology
放射線科(腫瘤) Radiation Oncology 放射線科(核醫) Nuclear Medicine
病理科(解剖) Pathology-Anatomic 病理科(臨床) Pathology-Clinical
核子醫學科 Nuclear Medicine 急診醫學科 Emergency Medicine
整形外科 Plastic Surgery 職業醫學科 Occupational Medicine
一般科 General 其他 Other
牙科 Dentistry 口腔病理科 Oral Pathology
口腔顎面外科 Oral and Maxillofacial Surgery 中醫 Traditional Chinese Medicine

語言治療師 Speech Therapist 牙體技術師 Dental Technologist
聽力師 Audiologist 牙體技術生 Dental Technician
西醫師 Physician 中醫師 Traditional Chinese Physician
牙醫師 Dentist 藥師 Pharmacist
藥劑生 Pharmacy Assistant 護理師 Registered Nurse
護士 Nursing Assistant 助產士 Mid-wife
助產師 Nurse Mid-wife 醫事檢驗師 Medical and Clinical Technologist
醫事檢驗生 Medical and Clinical Technician 鑲牙生 0
中藥員 0 齒模員 0
非醫事人員 Non-Medical 接骨員 0
物理治療師 Physical Therapist 職能治療師 Occupational Therapist
醫事放射師 Radiology Technologist 醫事放射士 Radiology Technician
物理治療生 PT Assistant 呼吸治療師 Respiratory Therapist
職能治療生 OT Assistant 諮商心理師 Counseling Psychologist
臨床心理師 Clinical Psychologist 營養師 Nutritionist

行政院衛生署 專科醫師制度
歷年專科醫師核證人數


臺灣醫學會 專科醫學會
中華民國醫師公會全國聯合會 專科醫學會

家庭醫學科 台灣家庭醫學醫學會
內科 台灣內科醫學會
外科 台灣外科醫學會
小兒科 臺灣兒科醫學會
婦產科 台灣婦產科醫學會
骨科 中華民國骨科醫學會
神經外科 台灣神經外科醫學會
泌尿科 台灣泌尿科醫學會
耳鼻喉科 台灣耳鼻喉科醫學會
眼科 中華民國眼科醫學會
皮膚科 臺灣皮膚科醫學會
神經科 台灣精神醫學會
精神科 台灣神經學學會
復健科 台灣復健醫學會
麻醉科 台灣麻醉醫學會
放射線(診斷)科 中華民國放射線醫學會
放射線(腫瘤)科 台灣放射腫瘤學會
病理(解剖)科 台灣病理學會
病理(臨床)科 台灣臨床病理檢驗醫學會
核子醫學科 中華民國核醫學學會
整形外科 台灣整形外科醫學會
急診醫學科 台灣急診醫學會
職業醫學科 中華民國環境職業醫學會

牙醫 中華牙醫學會
口腔顎面外科 中華民國口腔顎面外科學會
口腔病理科 中華民國口腔病理學會

European Union of Medical Specialists
UEMS Specialist Sections
Multidisciplinary Joint Committee
Clinical Genetics
Emergency Medicine
Hand Surgery
Immune Mediated Disease
Intensive Care Medicine
Oncology
Pain Medicine
Paediatric Urology 
Sexual Medicine
Spine Surgery
Sports Medicine 

Elderly care

Elderly care elder
Long-term_care 
Independent living 安養 
Assisted living 養護 
Nursing home 護理之家 長期照護 
Hospice 
Retirement community 



新竹 一里雲村 金色天地安養中心 
太平榮家 - 台東縣樂齡健康長照園區台東基督教醫院

台灣安養中心指南 

長照銀髮住宅觀察站 
潤福新象 康寧生活會館 長庚養生村 樂陶居

臺北市文山區養護機構 安養機構 
台北市政府社會局 銀髮族服務 福利據點 
台北市老人安養暨長期照顧機構一覽表 - 安養院 養護中心 長照 日照 
新北市政府社會局 失能老人日間照顧(護) 
中華民國老人福利推動聯盟 日間照顧縣市資源搜尋 
內政部 99年度老人福利機構評鑑成績 

臺北市政府社會局老人自費安養中心 Senior Homes, retirement housing 
台北市兆如老人安養護中心 安養 養護 長照 日照 
臺北市文山老人養護中心 養護 日照 
Maps 

台灣長期照護專業協會 如何選擇合適的照護 選擇機構三大原則 

台北市政府衛生局長期照顧資訊網 
行政院衛生署 護理及健康照護處 一般護理之家評鑑專區 
行政院衛生署 醫療資源 進階查詢 -> 護理機構 -> 護理之家 
老人福利機構與護理之家功能比較表 

Thursday, October 11, 2012

Cancer Clinical Trials

Women's Cancer Network Clinical Trials Gynecologic Oncology Group (GOG) Trials - incomplete
My Clinical Trial Locator: map

National Cancer Institute (NCI) Clinical Trials Search PDQ
NIH ClinicalTrials.gov Open Studies | Exclude Unknown | "Ovarian Neoplasms" with RSS feed link

Map of NCCN Member Institutions
- Stanford Clinical Trials (out of date)Ovarian/Peritoneal/Fallopian CancerGynecologic Cancers, Solid Tumor, Gynecology Clinical Research Group Eligibility Flowcharts
Phase 1 Clinical Research Program, Liquid biopsy 
- UCSF Gynecologic Oncology Clinical Trials including upcoming, ovarian cancer listsolid tumors list, flow-chart, UCSF clinical trialsovary search resultUCSF 500Liquid biopsy
UCSF Clinical Research Support Office Early Phase Clinical Trials UnitClinical and Translational Science Institute Early-Phase Clinical Trails UnitHematology and Oncology Research Earch Phase InitiativeLab
CPMC PAMF California Pacific Medical Center Gynecologic Cancer Clinical Trials
UCLA
City of Hope
USC

Coalition of Cancer Cooperative Groups (Cancer Trials Help) Trial Screening Questionnaire, sorted by distance

EmergingMed creating profile

Cancer.net American Society of Clinical Oncology (ASCO) Finding a Clinical Trial information only

CenterWatch - Commercial clinical trials listing service institutional review board (IRB)-approved trials

NCI Cancer Trials Support Unit (CTSU) - NCI-sponsored phase III cancer treatment trials limited to some GOG, RTOG

* Alkylating antineoplastic agent - Carboplatin - crosslinking of DNA - crosslinking inhibit DNA repair and/or DNA synthesis - hypothermia enhances the effect

* Mitotic inhibitor - prevent/stop cell division - Taxane
- GOG-212 Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer PAMF
- Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial.
History of Randomized Clinical Trials in Ovarian Cancer: Pre-Taxol Era, Taxol better for poorly-differentiated and late stage
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer resistance

- GOG-225 Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer SoCal

* HIPEC OVHIPEC info
Surgery and Heated Chemotherapy for Adrenocortical Carcinoma NIH HC 4/12/2013
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis M S-K 3/13/2013-
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer M S-K 1/10/2013
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers Columbia 7/10/2012
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix MD A 4/17/2012-
Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor MD A 1/12/2011

Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer 2007 Phase III Netherlands
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment 2011 hase III France

UC Irvine, Robert Bristow, Alessio Pigazzi, Kristine Penner
UCSD, Andrew Lowy, Joel Baumgartner, Kaitlyn Kelly
Sharp, Robert Barone
Loma Linda, Maheswari Senthil

* Whole-body Hyperthermia
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors (FR-WB-TT/che) UT HSC 9/13/2005
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer UT HSC 5/14/2004
Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer UT HSC 12/10/1999
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer UTH 11/1/1999

* Recurring platinum sensitive
California Trials search 
Califronia ovarian platinum Trials searchCalifornia Ovarian Recurrent search clinicaltrials.gov
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3), double blinded, Phase III, UCSF, PARP inhibitor
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer, phase I, Stanford
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2), Part 2 for 3 prior chemo only, Phase II, UCSF, gBRCA
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) suspended, Phase III, Stanford, UCSF anti-folic

* Resistant, Refractory
closed Virus
** - Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies (BYL719 Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor), Phase Ib, UCSF
** - Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours Phase I, measurable, Wee1 p53 tp53, UCSF 
** - A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Phase I, immune-resistant with taxol or platin, escalation, UCSF
* - Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Phase I, Flt3 mutation, CSF-1R inhibitor, with taxol, 2cm, UCSF  
* - A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors Phase I, RAS MAPK mutation, Cleave, UCSF
** - Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors, liquid biopsy, Stanford
* - Phase I Trial of Hu5F9-G4, anti CD47 gene, escalation Stanford 

Wee1: MK1775 3/26/2008, AZD1775 12/02/2012 PO
Chk1: Eli Lilly Prexasertib (LY2606368) IV NIH 4/28/2010
P53  Elephants' Cancer-Crushing Secrets May Someday Help People
Progress in p53-targeted drugs for ovarian cancer
Critical Outcomes Technologies Looks to Enter Clinical Race for p53 Drug to Treat Cancer
1.  Cellceutix Corp CTIX Kevetrin (thioureidobutyronitrile), Newstrials IV 8/2/2012 
2.  Aprea APR-246, trials IV 3/19/2014
3.  Critical Outcome Technologies, Inc COT COTI-2, COTI2 vs Kevetrin, News, trials PO, MDA, NWU, 4/27/2015

* Anti Cancer Stem Cell CSC
Novogen: Cantrixil News

Other:
- CT Antigen TCR-redirected T Cells for Ovarian Cancer Phase I-II, HLA A2 tissue type, Stanford
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Phase I, ROS1/ALK mutation, escalation, Stanford
NCI-MatchTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas, 5/31/2016 Phase II, PTEN with PI3K, StanfordPAMFCPMC Afatinib, AZD9291 Crizofinib Dabrafenib Trastuzumab Defactinib Sunitinib, NCORP November 2015 UpdateLots of Enthusiasm in Initial Months
- A Phase 1/2 Study to Evaluate MEDI4736 Phase I-II, Stanford lung
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase I, failed standard treatments, Stanford not recruiting
Study of ABT-165 in Subjects With Advanced Solid Tumors Phase I, UCDStanford breast
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies napabucasin Stemness Inhibitor Phase I, USC
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers Phase I, LA
Phase 1 Study of CM-24 (MK-6018) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Phase I, LA
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Phase II, UCSF for lung
- LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Phase II, not in UCD
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) Phase II, UCD phase II for Bladder/Urothelial Cancer
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens Phase II, PARP-inhibitor, *Stanford*, CPMC-SF* 
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR), ASCO (Michigan, Carolinas), Launched: Two of the Biggest Trials Yet for Precision Medicine
A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (PISH-2) Phase I, Lilja, verthermia

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (HIPEC/IPHC) Phase II, CDDP, Lilja, BAGO

PD-L1 Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), also search PDL1, PD-1, PD1, PD-L2, PDL2
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer (PemCiGem) phase 2, Cedar Sini
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 phase 1, Santa Monica
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) Phase 2, LA

- Cediranib Maleate and Olaparib 1-prior PAMF
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Phase I,II, up to 5 prior, Stanford
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL) Phase III, PFI 1-6 months, no more 3, StanfordNivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 3 prior including PARP, suspended, Phase II, antibody, CPMC-SF
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (CORAIL), random Topotecan, 3 prior, PFI at least 1 month, Phase III, PAMF, CPMC-SF
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2), PARP Part 2 for 3 prior chemo only, Phase II, UCSF, Stanford
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer MET-inhibitor, clear cell, Phase II, PAMF
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer clear cell Phase II, PAMF, CPMC
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers closed Phase I, Stanford, immunotherapy
GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Phase I, II, UCSF, not BRAF mutant
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer closed Reolysin (oncolytic reovirus) PAMF
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer only 1 prior chemo, Phase II, John Muir Health, Concord
- Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer clear cell, Phase II, BAF250a, UCSF, CPMC, PAMF

* Gemzar 1000mg/m^2 day1,8 + Carboplatin AUC 4 (Cisplatin 75mg/m^2) day 1 + Bevacizumab 15mg day 1 (A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)Guidelines for Hospitalization for Chemotherapy outpatient
6-month chemo-free 
.. PAMF trial

Metformin Hydrochloride Metformin is anti-diabetic medication to treat diabetes mellitus
Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer - Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature
Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule
A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy 9/4/2012 San Francisco

IDO is an enzyme which causes deplition of tryptophan which causes halted growth of T-cells
How Our Immune System Can Help Fight Cancer (ovarian)
1. Incyte IDO1 A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line ChemotherapyA Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma (not active A Dose-escalation Study in Subjects With Advanced Malignancies phase I)
2. IDO pathway inhibitor NewLink Genetics active: Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer, (terminated DO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT) phase I, paper Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer)

Late-stage ovarian cancer Novel treatment strategies have yielded several promising agents that have reached phase III
New perspectives on targeted therapy in ovarian cancer 2/2015

*Angiogenesis inhibitor
Bevacizumab 4/6/2000
-- Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer - targeting extracellular receptors by the antibody aflibercept or the peptibody trebananib, the multikinase inhibitors pazopanib, nintedanib, cediranib, sunitinib, and sorafenib 
-- Angiogenesis Foundationvideos
-- Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment OncLive list of clinical trials
TRINOVA-2: Trebananib in Ovarian Cancer-2 with PLD, Phase III, San Francisco SF
- GOG-0213 with Gemcitabine
- nintedanib BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
A clinical experience of single agent bevacizumab in relapsing ovarian cancer 2013 The PFS tended to be better in patients who experienced grade 3-4 arterial hypertension during the first month of treatment (median: 10ms) compared to patients who did not (median: 3ms)
Targeted anti-vascular therapies for ovarian cancer: current evidence 2013 Bevacizumab beyond progression
Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer 2014 OCEANS trial
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer 2014
-1 Ovarian Cancer Subtypes May Predict Response to Bevacizumab - Prognostically relevant gene signatures of high-grade serous ovarian carcinoma - (proliferative, mesenchymal) > (immunoreactive, differentiated [CA125])  - Nature: Integrated genomic analyses of ovarian carcinoma
-2 Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab - AADx assay (Almac Group Ltd) - 3 subgroups (pro-angiogenic subgroups > immune response)
-A Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy (Bevacizumab)
bevacizumab and hypertension avastin
Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
Treatment of bevacizumab-induced hypertension by amlodipine
Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Achieving better blood pressure control
Isolated Diastolic Hypertension 2007, Isolated Diastolic Hypertension 1995 (no systolic hypertension)
Seeking Alpha: Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?

PARP inhibitor for BRCA, PTEN
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Phase 2, UCSF
Olaparib BRCA with chemo since 6/27/2007Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1) phase 3, finished

Trabectedin + Doxil

* Immunotherapy Vaccine
- Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy Phase II, III with mucin 1 gene, Stanford
- Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer Oregon
- Phase Ib Trial of Folate Binding Protein Vaccine in Ovarian Cancer Ease Coast
- Ovarian Cancer Vaccine for Patients in Remission Phase II, closed

* Antifolate
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) Phase III, Stanford, SF, suspended
Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer Phase II, NY

* Palliative
UHC
ECHPalliative Care
PAMF, Palliative Care
Stanford Cancer Center Palliative Medicine Clinic
UCSF cancer symptom management
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options 2013

腹部腫脹, 食慾不振, 無法排便: 談婦癌病患的腸阻塞問題 bowel obstructionOvarian cancer Palliative care
** Pharmacologic Pearls for End-of-Life Care Morphine, Lorazepam, Compazine, Octreotide 0.3mg/day (papers), Levsin
Malignant Bowel Obstruction Guide, bowel obstruction, edema, ascites, constipation: total parenteral nutrition TPN, gastrostomy, octreotide
Fraser Health Hospice Palliative Care Symptom Guidelines for Nausea and Vomiting, dopamine D2, (Prochlorperazine [Compazine]) , 5-HT3 Ondansetron, Zophran, Hyoscyamine (Levsin)
Doctor, Does This Mean I'm Going to Starve to Death?
Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement
Palliative care in patients with ovarian cancer and bowel obstruction
Parenteral Nutrition in Malignant Bowel Obstruction: An Ethical Dilemma in Palliative Care
Gastrointestinal Complications
Palliative surgery for intestinal obstruction due to recurrent ovarian cancer
How Do You Triage Abdominal Pain in a Patient With Ovarian Cancer? small bowel obstruction SBO

Death Signs
** Bedside clinical signs associated with impending death in patients with advanced cancer: Preliminary findings of a prospective, longitudinal cohort study nonreactive pupils, a decreased response to verbal stimuli, a decreased response to visual stimuli, an inability to close eyelids, drooping of the nasolabial fold, hyperextension of the neck, grunting of vocal cords, and upper gastrointestinal bleeding
*台灣文化中末期癌症病人臨終症狀之探討 Clinical signs and symptoms on end-of-life for terminally ill cancer patients in Taiwanese culture, 臨終症狀發生率由高至低依序為:發紺冰冷(98.3%),至死亡日平均3.4天;鏡面舌(93.4%),至死亡日平均8.5天;耳垂縮(93.4%),至死亡日平均5.6天;陳氏呼吸(91.7%),至死亡日平均0.53天;煩躁不安(78.5%),至死亡日平均7.7天;死前嘎嘎聲(Death rattle)(65.2%),至死亡日平均0.89天;陰莖(囊)縮(54.4%),至死亡日平均10.1天;末期躁動(37.1%),至死亡日平均9.9天;鞏膜水腫(33.1%),至死亡日平均10.1天;譫妄(28.9%),至死亡日平均9.4天;夢到過世親人(11.5%),至死亡日平均11.4天。
*Predicting Active Dying The median time until death following the death rattle was 57 (+ or - 23, SD) hours, 7.6 (2.5) hours following respiration with mandibular movement, 5.1 (1.0) hours following cyanosis, and 2.6 (1.0) hour following lack of radial pulse. 

* Radiation Therapy
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Phase II, UCSF
Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer Phase II, Germany

* Topoisomerase inhibitor
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Texas, NM

* BRCA
BRCA2 >> (BRCA1,none)
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.

* Bevacizumab completed or not recruiting
GOG-218 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer 2005, 22-course maintenance
GOG-252 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer 2009 dose-dense, 16-course maintenance
GOG-241 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer (mEOC/GOG-0241) 2010, 12-course maintenance
GOG-262 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer 2010

Vascular Disrupting Agent (VDA) presentation
Zybrestat (Fosbretabulin tromethamine trial)
Bionomics BNC105 (BNC105P trial)